Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the District of Delaware on behalf of shareholders of The Chemours Company who purchased shares between February 2, 2026 and August 4, 2026.
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” CFO Shane Hostetter added that, “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year.”
On this news, the price of Chemours’ shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until December 7, 2026 to request that the court appoint them lead plaintiff.